1. Home
  2. SPT vs EVO Comparison

SPT vs EVO Comparison

Compare SPT & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SPT

Sprout Social Inc

HOLD

Current Price

$11.45

Market Cap

633.9M

Sector

Technology

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$3.12

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SPT
EVO
Founded
2010
1993
Country
United States
Germany
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
633.9M
1.1B
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
SPT
EVO
Price
$11.45
$3.12
Analyst Decision
Buy
Strong Buy
Analyst Count
10
1
Target Price
$26.00
$7.00
AVG Volume (30 Days)
1.0M
253.9K
Earning Date
11-05-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$443,750,000.00
$887,396,457.00
Revenue This Year
$13.30
N/A
Revenue Next Year
$11.37
$8.52
P/E Ratio
N/A
N/A
Revenue Growth
13.09
N/A
52 Week Low
$9.16
$2.84
52 Week High
$35.18
$4.80

Technical Indicators

Market Signals
Indicator
SPT
EVO
Relative Strength Index (RSI) 59.12 50.78
Support Level $10.97 $3.03
Resistance Level $12.06 $3.18
Average True Range (ATR) 0.45 0.08
MACD 0.04 0.04
Stochastic Oscillator 62.62 83.87

Price Performance

Historical Comparison
SPT
EVO

About SPT Sprout Social Inc

Sprout Social Inc develops a cloud software that brings together social messaging, data and workflows in a unified system of record, intelligence, and action. It has a centralized, secure and powerful platform that can scale horizontally across an organization to drive maximum business value. The firm generates majority revenue from software subscriptions.

About EVO Evotec SE

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

Share on Social Networks: